Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma to Present at Upcoming Investor Conferences in September
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
View HTML
Toggle Summary RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn’s Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
View HTML
Toggle Summary RedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights
Key Highlights and Upcoming Milestones: U.S. FDA acceptance of the New Drug Application (NDA) for Talicia ® for H. pylori for priority review and assignment of a target PDUFA action date of November 2, 2019   Preparations ongoing for the potential U.S. ...
View HTML
Toggle Summary RedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019
TEL-AVIV, Israel and RALEIGH, N.C. , July 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...
View HTML
Toggle Summary RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®
U.S. FDA accepts NDA for priority review   PDUFA date set for November 2, 2019   H. pylori infection affects approximately 35% of the U.S. population and is the strongest risk factor for the development of gastric cancer and a major risk factor for peptic ulcer disease and MALT lymphoma TEL-AVIV, ...
View HTML
Toggle Summary RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
The new patent expands the robust patent portfolio covering RHB-104 and RHB-204   RedHill plans to initiate a pivotal Phase 3 study with RHB-204 for the treatment of pulmonary nontuberculous mycobacteria (NTM) infections in the second half of 2019   RedHill plans to meet with the FDA in the second ...
View HTML
Toggle Summary RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer
TEL-AVIV, Israel and RALEIGH, N.C. , May 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced the appointment of Dr. ...
View HTML
Toggle Summary RedHill Biopharma to Present at 2019 BIO International Convention
TEL-AVIV, Israel and RALEIGH, N.C. , May 23, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. ...
View HTML
Toggle Summary RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch
Rob Jackson joins as Vice President of Marketing Robert J. Gilkin, Jr. joins as Vice President of Market Access Steven Thomasian to join as Vice President of Supply Chain TEL-AVIV, Israel and RALEIGH, N.C. , May 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ...
View HTML
Toggle Summary RedHill Biopharma Reports First Quarter 2019 Financial Results and Operational Highlights
Key Highlights and Upcoming Milestones: NDA submitted to the FDA for Talicia ® for H. pylori infection, with potential U.S. commercial launch in Q4/2019, assuming FDA approval FDA meeting planned for H2/2019 to discuss design of confirmatory Phase 3 study and path to potential approval for RHB-104 ...
View HTML